Literature DB >> 22962914

Reducing adverse effects of proton pump inhibitors.

Paul W Ament1, Daniel B Dicola, Mary E James.   

Abstract

Proton pump inhibitors effectively treat gastroesophageal reflux disease, erosive esophagitis, duodenal ulcers, and pathologic hypersecretory conditions. Proton pump inhibitors cause few adverse effects with short-term use; however, long-term use has been scrutinized for appropriateness, drug-drug interactions, and the potential for adverse effects (e.g., hip fractures, cardiac events, iron deficiency, Clostridium difficile infection, pneumonia). Adults 65 years and older are more vulnerable to these adverse effects because of the higher prevalence of chronic diseases in this population. Proton pump inhibitors administered for stress ulcer prophylaxis should be discontinued after the patient is discharged from the intensive care unit unless other indications exist.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22962914

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  14 in total

Review 1.  Stress ulcer prophylaxis, thromboprophylaxis and coagulation management in patients with hip fractures.

Authors:  Heinrich Wolfgang Thaler; Peter Dovjak; Bernhard Iglseder; Georg Pinter; Ernst Müller; Walter Müller; Katharina Pils; Peter Mikosch; Inge Gerstorfer; Michaela Zmaritz; Monique Weissenberger-Leduc; Markus Gosch
Journal:  Wien Med Wochenschr       Date:  2013-09-04

2.  PURLs: The benefits--and limits--of PPIs with warfarin regimens.

Authors:  Alicia Ludden-Schlatter; James J Stevermer
Journal:  J Fam Pract       Date:  2017-11       Impact factor: 0.493

3.  Immunosuppressive agents are associated with peptic ulcer bleeding.

Authors:  Minoru Tomizawa; Fuminobu Shinozaki; Rumiko Hasegawa; Yoshinori Shirai; Yasufumi Motoyoshi; Takao Sugiyama; Shigenori Yamamoto; Naoki Ishige
Journal:  Exp Ther Med       Date:  2017-03-09       Impact factor: 2.447

4.  Prevention and Treatment of NSAID Gastropathy.

Authors:  Carla J Gargallo; Carlos Sostres; Angel Lanas
Journal:  Curr Treat Options Gastroenterol       Date:  2014-12

5.  Use of proton pump inhibitors and subsequent risk of celiac disease.

Authors:  Benjamin Lebwohl; Stuart J Spechler; Timothy C Wang; Peter H R Green; Jonas F Ludvigsson
Journal:  Dig Liver Dis       Date:  2013-09-12       Impact factor: 4.088

Review 6.  Deprescribing versus continuation of chronic proton pump inhibitor use in adults.

Authors:  Taline A Boghossian; Farah Joy Rashid; Wade Thompson; Vivian Welch; Paul Moayyedi; Carlos Rojas-Fernandez; Kevin Pottie; Barbara Farrell
Journal:  Cochrane Database Syst Rev       Date:  2017-03-16

7.  A clinical drug-drug interaction study to evaluate the effect of a proton-pump inhibitor, a combined P-glycoprotein/cytochrome 450 enzyme (CYP)3A4 inhibitor, and a CYP2C9 inhibitor on the pharmacokinetics of vismodegib.

Authors:  Vikram Malhi; Dawn Colburn; Sarah J Williams; Cornelis E C A Hop; Mark J Dresser; Priya Chandra; Richard A Graham
Journal:  Cancer Chemother Pharmacol       Date:  2016-05-06       Impact factor: 3.333

8.  Inflammatory bowel disease, high-dose steroids, osteoporosis, or an oncological etiology for a pathological femoral neck fracture in a young adult: a case report.

Authors:  Brandon Raudenbush; Ian Walton; Ashley Simela; Michael Retino
Journal:  Open Orthop J       Date:  2014-02-07

9.  Predictors for mortality from respiratory failure in a general population.

Authors:  Maki Kobayashi; Yoko Shibata; Sumito Inoue; Akira Igarashi; Kento Sato; Masamichi Sato; Takako Nemoto; Yuki Abe; Keiko Nunomiya; Michiko Nishiwaki; Yoshikane Tokairin; Tomomi Kimura; Makoto Daimon; Naohiko Makino; Tetsu Watanabe; Tsuneo Konta; Yoshiyuki Ueno; Takeo Kato; Takamasa Kayama; Isao Kubota
Journal:  Sci Rep       Date:  2016-05-16       Impact factor: 4.379

10.  Protective effect of Rhei Rhizoma on reflux esophagitis in rats via Nrf2-mediated inhibition of NF-κB signaling pathway.

Authors:  O Jun Kwon; Byung Kil Choo; Joo Young Lee; Min Yeong Kim; Sung Ho Shin; Bu-Il Seo; Young-Bae Seo; Man Hee Rhee; Mi-Rae Shin; Gyo-Nam Kim; Chan Hum Park; Seong-Soo Roh
Journal:  BMC Complement Altern Med       Date:  2016-01-09       Impact factor: 3.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.